Cullinan Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 109

Employees

  • Stock Symbol
  • CGEM

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $8.89
  • (As of Friday Closing)

Cullinan Therapeutics General Information

Description

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Contact Information

Formerly Known As
Cullinan Management, Cullinan Oncology
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1 Main Street
  • Suite 1350
  • Cambridge, MA 02142
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1 Main Street
  • Suite 1350
  • Cambridge, MA 02142
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cullinan Therapeutics Stock Performance

As of 20-Nov-2026, Cullinan Therapeutics’s stock price is $8.89. Its current market cap is $577M with 64.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.89 $9.07 $8.47 - $23.19 $577M 64.9M 993K -$3.08

Cullinan Therapeutics Financials Summary

As of 30-Sep-2026, Cullinan Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 655,378 280,031 133,580 (24,580)
Revenue 0 0 0 0
EBITDA (218,825) (241,780) (196,812) (190,540)
Net Income (203,466) (219,879) (167,383) (153,162)
Total Assets 322,559 448,374 621,824 484,182
Total Debt 2,004 2,683 2,151 3,590
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cullinan Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cullinan Therapeutics‘s full profile, request access.

Request a free trial

Cullinan Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and
Drug Discovery
Cambridge, MA
109 As of 2025

South San Francisco, CA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cullinan Therapeutics Competitors (57)

One of Cullinan Therapeutics’s 57 competitors is ORIC Pharmaceuticals, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ORIC Pharmaceuticals Formerly VC-backed South San Francisco, CA
Aura Biosciences Formerly VC-backed Boston, MA
Ayala Pharmaceuticals Corporation Wilmington, DE
Geron Formerly VC-backed Foster City, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
You’re viewing 5 of 57 competitors. Get the full list »

Cullinan Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cullinan Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cullinan Therapeutics‘s full profile, request access.

Request a free trial

Cullinan Therapeutics Investments (2)

Cullinan Therapeutics’s most recent deal was a Secondary Transaction - Private with Cullinan Mica for . The deal was made on 25-Oct-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cullinan Mica 25-Oct-2022 Secondary Transaction - Private Drug Delivery
Cullinan Mica 11-Jun-2020 Later Stage VC Drug Delivery
To view Cullinan Therapeutics’s complete investments history, request access »

Cullinan Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.73 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Cullinan Therapeutics’s complete esg history, request access »

Cullinan Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Cullinan Pearl Cambridge, MA

Cullinan Therapeutics FAQs

  • When was Cullinan Therapeutics founded?

    Cullinan Therapeutics was founded in 2016.

  • Where is Cullinan Therapeutics headquartered?

    Cullinan Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Cullinan Therapeutics?

    Cullinan Therapeutics has 109 total employees.

  • What industry is Cullinan Therapeutics in?

    Cullinan Therapeutics’s primary industry is Drug Discovery.

  • Is Cullinan Therapeutics a private or public company?

    Cullinan Therapeutics is a Public company.

  • What is Cullinan Therapeutics’s stock symbol?

    The ticker symbol for Cullinan Therapeutics is CGEM.

  • What is the current stock price of Cullinan Therapeutics?

    As of 20-Nov-2026 the stock price of Cullinan Therapeutics is $8.89.

  • What is the current market cap of Cullinan Therapeutics?

    The current market capitalization of Cullinan Therapeutics is $577M.

  • Who are Cullinan Therapeutics’s competitors?

    ORIC Pharmaceuticals, Aura Biosciences, Ayala Pharmaceuticals, Geron, and Kite Pharma are some of the 57 competitors of Cullinan Therapeutics.

  • What is Cullinan Therapeutics’s annual earnings per share (EPS)?

    Cullinan Therapeutics’s EPS for 12 months was -$3.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process